Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei

European Journal of Surgical Oncology

Volumn 36, Issue 12, 2010, Pages 1156-1161

  Alves, S ^a   Mohamed, F ^a   Yadegarfar, G ^a,b   Youssef, H ^a   Moran, B J ^a  

^a BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Appendiceal malignancy; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Quality of life

Indexed keywords

FLUOROURACIL; MITOMYCIN C; ANTINEOPLASTIC AGENT;

ADULT; AGED; APPETITE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; MORBIDITY; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; WELLBEING; ADJUVANT CHEMOTHERAPY; HEALTH STATUS; HYPERTHERMIC THERAPY; INFUSION; METHODOLOGY; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; HEALTH STATUS; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMYXOMA PERITONEI; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952051422     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.09.004     Document Type: Article

References (21)

1. National Institute for Health and Clinical Excellence (NICE). Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) 2004;.http://www.nice.org.uk/Guidance/IPG56.
2. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 2008;34:196-201.
3. Moran BJ, CecilTD. The etiology, clinical presentation, andmanagement of pseudomyxoma peritonei. Surg Oncol Clin N Am 2003;12:585-603. (Pubitemid 36920087)
4. Hinson FL, Ambrose NS. Pseudomyxoma peritonei. Br J Surg 1998; 85:1332-9. (Pubitemid 28468332)
5. Sugarbaker PH, Kern K, Lack E. Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. Dis Colon Rectum 1987;30:772-9. (Pubitemid 17168045)
6. Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg 1989;32:164-70. (Pubitemid 19152802)
7. Moran BJ, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 2006;93:100-4. (Pubitemid 43117313)
8. McQuellon RP, Loggie BW, Fleming RA, Russel GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001; 27:65-73. (Pubitemid 32229697)
9. McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003;10:155-62. (Pubitemid 40485936)
10. McQuellon RP, Russell GB, Shen P, Stewart JH. th, Saunders W, Levine EA. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol 2008;15: 125-33.
11. Jess P, Iversen LH, Nielsen MB, Hansen F, Lauerberg S, Rasmussen PC. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 2008;51:868-74.
12. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-oflife instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. (Pubitemid 23073154)
13. Fayers PM, Aaronson NK, Bjordal K, Curran D, Groenvold M. EORTC QLQ-C30 scoring manual. 2nd ed. 1999;. Brussels.
14. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44. (Pubitemid 28041591)
15. Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg 2006;93:1270-6. (Pubitemid 44547028)
16. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 2007; 245:104-9. (Pubitemid 46035441)
17. Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2008;15:526-34.
18. Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum 2007;50:37-42. (Pubitemid 46147019)
19. Elias D, Honore C, Ciuchendea R, et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg 2008;95: 1164-71.
20. Stewart JHt, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006;13: 624-34.
21. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004;240:278-85. (Pubitemid 38963019)